EGFR and skin squamous cell carcinoma: Therapy for cSCC with EGFR inhibitors, including monoclonal antibodies (e.g., cetuximab and panitumumab) and tyrosine kinase inhibitors (gefitinib and erlotinib), has emerged as a promising approach.